Scholarlink

Objective <p>Steroid-resistant immune checkpoint inhibitor (ICI)-associated myocarditis (ICIAM) is rare, with no effective therapy. We present a case of successfully managed steroid-resistant ICIAM, demonstrating an effective treatment for this life-threatening complication.</p> Case report <p>A 77-year-old woman with intrahepatic cholangiocarcinoma developed myocardial injury after two doses of ICI treatment. There was a rebound in troponin T during corticosteroid therapy; consequently, the patient was treated with tofacitinib combined with mycophenolate mofetil as second-line immunosuppressive therapy. Outcomes improved and anti-tumor treatment was rechallenged.</p> Conclusion <p>The early administration of second-line immunosuppressive therapy is crucial for good outcomes with steroid-resistant ICIAM and the subsequent rechallenge of anti-tumor therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Steroid-resistant immune checkpoint inhibitor-associated myocarditis: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月6日

查看全文
  • Xiaozhen He,
  • Yerui Zhang,
  • Yan Wang,
  • Huiyong Chen,
  • Yuan Liu,
  • Leilei Cheng

摘要

Objective

Steroid-resistant immune checkpoint inhibitor (ICI)-associated myocarditis (ICIAM) is rare, with no effective therapy. We present a case of successfully managed steroid-resistant ICIAM, demonstrating an effective treatment for this life-threatening complication.

Case report

A 77-year-old woman with intrahepatic cholangiocarcinoma developed myocardial injury after two doses of ICI treatment. There was a rebound in troponin T during corticosteroid therapy; consequently, the patient was treated with tofacitinib combined with mycophenolate mofetil as second-line immunosuppressive therapy. Outcomes improved and anti-tumor treatment was rechallenged.

Conclusion

The early administration of second-line immunosuppressive therapy is crucial for good outcomes with steroid-resistant ICIAM and the subsequent rechallenge of anti-tumor therapy.